Enrolling by invitationNCT07450040

Efficacy and Safety of Tislelizumab Combined With Gemcitabine and Peraspartase in the Treatment of Patients With Primary Stage I-II NK/T Cell Lymphoma

Studying Extranodal nasal NK/T cell lymphoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Eye & ENT Hospital of Fudan University
Enrollment
60 enrolled
Eligibility
18-70 years · All sexes
Timeline
20242027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07450040 on ClinicalTrials.gov

Other trials for Extranodal nasal NK/T cell lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Extranodal nasal NK/T cell lymphoma

← Back to all trials